Literature DB >> 19221694

Wound healing delay after central venous access following DCF/VEGF-trap therapy.

Charles Ferté1, Christophe Massard, Christian Moldovan, Eric Desruennes, Yohann Loriot, Jean-Charles Soria.   

Abstract

Hypertension, proteinuria, thromboembolic or bleeding events are well-recognized complications occurring while targeting VEGF pathway. Wound healing dysfunctions have also been described in patients undergoing major surgery. For the first time, we report wound healing delay after central venous access following DCF-VEGF-Trap. VEGF-Trap may affect both angiogenesis and reepithelialization which are necessary to the normal repair process.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19221694     DOI： 10.1007/s10637-009-9227-7

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  10 in total

Review 1.  Cutaneous wound healing.

Authors:  A J Singer; R A Clark
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

2.  Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.

Authors:  Frank A Scappaticci; Louis Fehrenbacher; Thomas Cartwright; John D Hainsworth; William Heim; Jordan Berlin; Fairooz Kabbinavar; William Novotny; Somnath Sarkar; Herbert Hurwitz
Journal:  J Surg Oncol       Date:  2005-09-01       Impact factor: 3.454

Review 3.  Vascular endothelial growth factor trap in non small cell lung cancer.

Authors:  Gregory J Riely; Vincent A Miller
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

4.  Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.

Authors:  Limin Hu; Judith Hofmann; Jocelyn Holash; George D Yancopoulos; Anil K Sood; Robert B Jaffe
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

5.  Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy.

Authors:  R L Poorter; F N Lauw; W A Bemelman; P J Bakker; C W Taat; C H Veenhof
Journal:  Eur J Cancer       Date:  1996-12       Impact factor: 9.162

Review 6.  Vascular permeability, vascular hyperpermeability and angiogenesis.

Authors:  Janice A Nagy; Laura Benjamin; Huiyan Zeng; Ann M Dvorak; Harold F Dvorak
Journal:  Angiogenesis       Date:  2008-02-22       Impact factor: 9.596

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  VEGF blockade inhibits angiogenesis and reepithelialization of endometrium.

Authors:  Xiujun Fan; Sacha Krieg; Calvin J Kuo; Stanley J Wiegand; Marlene Rabinovitch; Maurice L Druzin; Robert M Brenner; Linda C Giudice; Nihar R Nayak
Journal:  FASEB J       Date:  2008-07-07       Impact factor: 5.191

9.  Risk factors for early catheter-related infections in cancer patients.

Authors:  Nicolas Penel; Jean-Charles Neu; Stéphanie Clisant; Helga Hoppe; Patrick Devos; Yazdan Yazdanpanah
Journal:  Cancer       Date:  2007-10-01       Impact factor: 6.860

Review 10.  Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy.

Authors:  Mayumi Ono
Journal:  Cancer Sci       Date:  2008-08       Impact factor: 6.716
  10 in total
  1 in total

1.  Dysphonia induced by vascular endothelium growth factor/vascular endothelium growth factor receptor inhibitors.

Authors:  Dana M Hartl; Charles Ferté; Yohann Loriot; Carlos Gomez Roca; Rastislav Bahleda; Cristian Moldovan; Olivier Mir; Jean-Charles Soria
Journal:  Invest New Drugs       Date:  2009-09-16       Impact factor: 3.850
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.